Trethera Corp. received a $2.7M NIH grant to study combining TRE-515 with KRAS inhibitors for lung cancer. Learn how this ...

The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. | The emergence of ...

The RAMP 203 trial in advanced KRAS G12C–mutated non-small cell lung cancer has been discontinued due to increased ...

Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...

Early-stage non-small cell lung cancer (NSCLC) offers a better prognosis than advanced stages. Staging helps inform treatment by describing your cancer's size, lymph node involvement, and metastasis.

The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...

Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical ...

Ask a clinical question and tap into Healio AI's knowledge base. Lung cancer is generally the top cause of cancer-related death globally and in the United States (US). In the US in 2023, lung cancer ...

If you or a loved one has lung cancer, you may be interested in learning more about medicines used to treat it. One option is an immunotherapy medicine called Imfinzi (durvalumab). Immunotherapy ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...

Ask a clinical question and tap into Healio AI's knowledge base. Lung cancer in general, and non-small cell lung cancer (NSCLC) in particular, is often asymptomatic in the early stages of the disease.